RGD-4C is a cell-adhesive peptide that binds αvβ3 and αvβ5 integrins; these integrins are overexpressed in many cancers and growing vessels, so RGD-4C is often attached to viral treatments to better deliver or target the treatment to cancerous tissues. RGD-4C exhibits anticancer chemotherapeutic and anti-angiogenic benefits in models of various cancers, including non-small cell lung cancer (NSCLC), melanoma, and glioma.
| Purity | ≥95% |
|---|---|
| Formula | C42H60N14O16S4 |
| Formula Wt. | 1145.29 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | R2510 Info Sheet PDF |
|---|
Allaume X, El-Andaloussi N, Leuchs B, et al. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J Virol. 2012 Apr;86(7):3452-65. PMID: 22258256.
Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer. 2012 Apr 15;130(8):1937-47. PMID: 21630267.
Sarkioja M, Kanerva A, Salo J, et al. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer. 2006 Oct 1;107(7):1578-88. PMID: 16948124.
Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg. 2006 Apr;104(4):583-92. PMID: 16619663.
